Mayne Pharma Group Limited (MAYNF)

4,4600 0,0000 (0,00%) Börsenschluss: 09:30AM EDT

Mayne Pharma Group Limited

1538 Main North Road
Salisbury South, SA 5106
Australia
61 8 8209 2666
https://www.maynepharma.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Shawn Patrick O'Brien B.Sc	CEO, MD & Director	827,32k	N/A	1959
Mr. Aaron Gray	Chief Financial Officer	694k	N/A	N/A
Ms. Kimberly Parker J.D.	Executive VP & General Counsel	N/A	N/A	N/A
Mr. Brant Schofield	Executive Vice President of Corporate Development	676,75k	N/A	1966
Ms. Erinn Nathaniel	Director of Global Human Resources	N/A	N/A	N/A
Mr. Daniel Moore	Executive Vice President of Commercial	N/A	N/A	N/A
Dr. Frank Casty M.D.	Executive VP & Global Chief Medical Officer	N/A	N/A	N/A
Mr. Brenton Walter	Financial Controller	N/A	N/A	N/A
Ms. Laura Loftus	Associate General Counsel & Company Secretary	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Corporate Governance

Mayne Pharma Group Limiteds ISS Governance QualityScore, Stand 1. April 2024, lautet 5. Die grundlegenden Scores sind Audit: 5, Vorstand: 3, Shareholderrechte: 7, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.